Full Press Release Details
CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will participate in the following upcoming March investor conferences:
Citizens Life Sciences Conference
Date: Tuesday, March 10, 2026Format: Fireside chat and 1x1 meetingsTime: 9:00 a.m. – 9:25 a.m. ETLocation: Miami, FL
UBS Biotech Summit Miami – Catalyst for Change
Date: Tuesday, March 10, 2026Format: 1x1 meetings onlyLocation: Miami, FL
Jefferies Biotech on the Beach Summit
Date: Wednesday, March 11, 2026Format: 1x1 meetings onlyLocation: Miami, FL
Barclays 28thGlobal Healthcare Conference
Date: Wednesday, March 11, 2026Format: Fireside chat and 1x1 meetingsTime: 3:00 p.m. – 3:25 p.m. ETLocation: Miami, FL
The live webcasts, where available, can be accessed in the events section of the MBX Biosciences website athttps://investors.mbxbio.com/news-events/events. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX BiosciencesMBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana. To learn more, please visit the Company website atwww.mbxbio.comand follow it onLinkedIn.